Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major

This study has been terminated.
Sponsor:
Information provided by:
Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier:
NCT00007072
First received: December 6, 2000
Last updated: June 23, 2005
Last verified: October 2003

December 6, 2000
June 23, 2005
November 2000
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00007072 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major
Not Provided

OBJECTIVES:

I. Determine the safety and efficacy of azacitidine and phenylbutyrate in treatment of patients with thalassemia major.

PROTOCOL OUTLINE: Patients receive azacitidine IV continuously on days 1-4 and oral phenylbutyrate three times a day on days 14-42. Bone marrow needle aspiration is performed on days 6, 14, and 42 to assess disease response to treatment. If no response on day 42, a second course of azacitidine and phenylbutyrate begins 7 days later.

Patients are followed weekly for 3 months and then monthly thereafter.

Interventional
Phase 2
Primary Purpose: Treatment
Thalassemia Major
  • Drug: azacitidine
  • Drug: phenylbutyrate
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
24
Not Provided
Not Provided

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Diagnosis of thalassemia major Progressive disease defined as: Increasing transfusion requirement or difficulty in maintenance of hemoglobin levels greater than 7 g/dL as a consequence of autologous or allogeneic antibodies OR Increasing extramedullary hematopoiesis causing compression phenomena OR Disease with complications of iron overload despite traditional transfusion and iron chelation therapy (e.g., heart failure, decreased cardiac ejection fraction, endocrinopathy, or evidence of progressive liver dysfunction)

Standard transfusion therapy or iron chelation therapy must be contraindicated

--Prior/Concurrent Therapy--

See Disease Characteristics

--Patient Characteristics--

Performance status: ECOG 0-2

Life expectancy: Greater than 10 days Not moribund

Hematopoietic: See Disease Characteristics

Hepatic: See Disease Characteristics AST or ALT no greater than 3 times upper limit of normal (ULN) Bilirubin no greater than 1.5 times ULN (unless due to hemolysis or Gilbert's disease) Albumin at least 3 g/dL No severe concurrent hepatic disease

Renal: Creatinine no greater than 2 mg/dL Creatinine clearance at least 60 mL/min No severe concurrent renal disease

Cardiovascular: See Disease Characteristics No New York Heart Association class III or IV

Other: Not pregnant or nursing No severe concurrent metabolic disease No severe sepsis or septic shock No concurrent altered mental status or seizure disorder No concurrent myelodysplastic syndrome or leukemia

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00007072
199/15578, NIDDK-00-DK-0166, NCI-1311
Not Provided
Not Provided
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not Provided
Study Chair: Griffin Platt Rodgers National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Office of Rare Diseases (ORD)
October 2003

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP